Daridorexant

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Daridorexant (Quviviq) is a prescription sleep medicine that helps adults with insomnia fall asleep and stay asleep. It works differently from benzodiazepines and Z-drugs because it blocks the brain’s wake-promoting chemicals, orexin A and orexin B, at two receptors (OX1 and OX2). This makes it easier to sleep without acting on GABA receptors.

How you take it
- Taken by mouth as a tablet. Available in 25 mg and 50 mg doses (as the salt daridorexant hydrochloride, with 27 mg or 54 mg salt equivalent).
- The usual dose is decided by a doctor (often 25 mg or 50 mg).

What it does
- Helps with sleep onset (time to fall asleep) and sleep maintenance (staying asleep).
- In clinical studies, 50 mg helped daytime functioning more than 25 mg.
- Peak effects usually occur about 1–2 hours after taking it. Food can slow the time to peak by about 1–2 hours.
- The drug’s effects last about 8 hours.

How it behaves in the body
- Oral bioavailability about 62%; it binds strongly to protein in the blood (about 99.7%).
- Metabolized mainly by the liver enzyme CYP3A4.
- Excreted mostly as metabolites: about 57% in feces and 28% in urine.
- Half-life is about 8 hours (roughly 6–10 hours); the half-life can be a bit longer in older adults.

Safety and side effects
- Common side effects include headache, sleepiness (somnolence), fatigue, dizziness, and nausea.
- There can be some morning impairment when starting treatment or for some people.
- It is not a first-line sleep aid for everyone and may have a lower overall benefit in some analyses compared with other medicines.
- It has a lower risk of withdrawal and rebound insomnia than some other sedatives, but continued use should be guided by a doctor.
- There is some potential for misuse, but it appears lower than for many other sleep medicines.

Drug interactions and cautions
- Avoid strong inhibitors or inducers of CYP3A4 (these can change how much daridorexant is in your body). If you use moderate inhibitors, your doctor may lower the dose.
- Strong CYP3A4 inhibitors (like certain antifungals or HIV medicines) or inducers (like rifampin) can significantly alter levels of the drug.
- Peak levels can be reduced by options that raise stomach pH or food; alcohol and some antidepressants may increase CNS depressant effects when taken with daridorexant.
- Not recommended for people with narcolepsy. Dose adjustments are often needed for those with moderate or severe liver problems.

Who can use it
- Approved for adults with insomnia characterized by trouble with sleep onset and/or sleep maintenance.
- US: approved in January 2022; EU: approved in April 2022; Canada: approved in 2023.
- In the US, it is a Schedule IV controlled substance.

What to know before using
- Discuss other medicines you take, especially CYP3A4 inhibitors or inducers.
- Tell your doctor if you have liver problems, are pregnant or breastfeeding, or have a history of substance use disorders.
- If you miss a dose, don’t double up; follow your physician’s guidance.

In short, daridorexant is a short-acting, non-GABA sleep medicine that helps adults with insomnia by blocking orexin signals in the brain. It can improve sleep and daytime function at the right dose, with manageable side effects and some important drug interactions to consider. Always use under a clinician’s supervision.